Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scil Proteins, an expertise in the development and production of recombinant proteins, has signed an agreement to manufacture Reteplase, a recombinant protein for Actavis.
Subscribe to our email newsletter
Reteplase is a recombinant protein and the active ingredient in the medicinal product Rapilysin, used for thrombolytic treatment of myocardial infarction.
Except in US and Canada, Actavis owns rights on the Reteplase production process and on Rapilysin for European and worldwide distribution.
In June 2008, Scil Proteins has partnered with Roche for process transfer and manufacture of Reteplase.
Actavis, a generic pharmaceutical company is specialized in the development, manufacture and sale of generic pharmaceuticals.